CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...